Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...

Susan Vadaparampil, PhD, MPH, of Moffitt Cancer Center, concludes her conversation with The American Journal of Managed Care® at last month’s Institute for Value-Based Medicine ® event in Tampa, ...

A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has synergized the impacts of worldwide ...

From bionic eyes to cell and gene therapies in clinical therapies, it's an exciting time for emerging technologies aiming to treat blindness and the visually impaired.

Even when promising clinical trials exist, and the FDA allows expanded access, rare disease patients like my granddaughter ...

Globally, millions of people are affected by Alzheimer's disease, with around 120,000 individuals in Norway alone. Witnessing ...

Human challenge trials offer a complementary approach. By safely and deliberately exposing healthy adult volunteers to a well characterised virus under controlled conditions, researchers can generate ...